Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
AJNR. American Journal of Neuroradiology
|
October 31, 2014
Degeneration and plasticity of the optic pathway in Alström syndrome
R Manara, V Citton, P Maffei, et al.
Journal of Endocrinological Investigation
|
January 22, 2025
The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism
G Occhi, G Voltan, S Chiloiro, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
December 29, 2022
[Evaluation of the results and feasibility of vibration, diuresis and inversion therapy in the treatment of upper urinary tract stones]
R Delonca, V Anastay, B Gondran-Tellier, et al.
Clinical Endocrinology
|
March 1, 2013
Alström syndrome is associated with short stature and reduced GH reserve
S Romano, P Maffei, V Bettini, et al.
Journal of Endocrinological Investigation
|
February 9, 2017
Pegvisomant in acromegaly: an update
A Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation
|
December 30, 2017
Correction to: Pegvisomant in acromegaly: an update
A Giustina, G Arnaldi, F Bogazzi, et al.
Clinical Endocrinology
|
February 24, 2001
Relationship between blood pressure and glucose tolerance in acromegaly
M L Jaffrain-Rea, C Moroni, R Baldelli, et al.
Journal of Endocrinological Investigation
|
April 1, 2022
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
S Grottoli, A Bianchi, F Bogazzi, et al.
Human Molecular Genetics
|
March 11, 1999
Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder
J Deckert, M Catalano, Y V Syagailo, et al.
Journal of Endocrinological Investigation
|
October 30, 2017
How to improve effectiveness of pegvisomant treatment in acromegalic patients
M Ragonese, S Grottoli, P Maffei, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
AJNR. American Journal of Neuroradiology
|
October 31, 2014
Degeneration and plasticity of the optic pathway in Alström syndrome
R Manara, V Citton, P Maffei, et al.
Journal of Endocrinological Investigation
|
January 22, 2025
The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism
G Occhi, G Voltan, S Chiloiro, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
December 29, 2022
[Evaluation of the results and feasibility of vibration, diuresis and inversion therapy in the treatment of upper urinary tract stones]
R Delonca, V Anastay, B Gondran-Tellier, et al.
Clinical Endocrinology
|
March 1, 2013
Alström syndrome is associated with short stature and reduced GH reserve
S Romano, P Maffei, V Bettini, et al.
Journal of Endocrinological Investigation
|
February 9, 2017
Pegvisomant in acromegaly: an update
A Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation
|
December 30, 2017
Correction to: Pegvisomant in acromegaly: an update
A Giustina, G Arnaldi, F Bogazzi, et al.
Clinical Endocrinology
|
February 24, 2001
Relationship between blood pressure and glucose tolerance in acromegaly
M L Jaffrain-Rea, C Moroni, R Baldelli, et al.
Journal of Endocrinological Investigation
|
April 1, 2022
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
S Grottoli, A Bianchi, F Bogazzi, et al.
Human Molecular Genetics
|
March 11, 1999
Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder
J Deckert, M Catalano, Y V Syagailo, et al.
Journal of Endocrinological Investigation
|
October 30, 2017
How to improve effectiveness of pegvisomant treatment in acromegalic patients
M Ragonese, S Grottoli, P Maffei, et al.
Page
of 7